The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Karyopharm Therapeutics
Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).
 
Christopher James Walker
Employment - Karyopharm Therapeutics
 
Shirong Li
No Relationships to Disclose
 
Yi Chai
Employment - Karyopharm Therapeutics
 
Jatin J. Shah
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
No Relationships to Disclose
 
Suzanne Lentzsch
Leadership - Caelum Biosciences
Stock and Other Ownership Interests - Caelum Biosciences
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Caelum Biosciences; Celularity; GlaxoSmithKline; Janssen; Sanofi; Sorrento Therapeutics; Takeda
Speakers' Bureau - Clinical Care Options/NCCN; PeerView
Research Funding - Karyopharm Therapeutics; Sanofi
Patents, Royalties, Other Intellectual Property - Patent 11-1F4 mAb for use in AL Amyloidosis
Travel, Accommodations, Expenses - Janssen
 
Yosef Landesman
Employment - Karyopharm Therapeutics